Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Columbus Clinical Services LLC

Neither a doctor nor a teaching hospital

Research payments

$5,436,184

896 payments

Through program year 2025, Columbus Clinical Services LLC is reported as receiving $5,436,184 in research payments, across 896 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $1,437,013 174
2024 Research $1,623,762 158
2023 Research $658,801 75
2022 Research $655,497 207
2021 Research $368,824 192
2020 Research $312,227 72
2019 Research $380,060 18

Breakdown

Who paid Research payments · program years 2019–2025
  1. Novartis Pharmaceuticals Corporation $1,656,441 12 payments
  2. Chiesi USA, Inc. $767,233 72 payments
  3. AbbVie, Inc. $705,963 116 payments
  4. GlaxoSmithKline, LLC. $369,162 82 payments
  5. Allergan Inc. $327,797 21 payments
  6. ITI, Inc. $312,916 109 payments
  7. AstraZeneca UK Limited $238,757 5 payments
  8. Esperion Therapeutics, Inc. $234,963 354 payments
  9. Pfizer Inc. $220,909 3 payments
  10. Abbott Laboratories $162,425 38 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) $1,292,466 4 payments
  2. A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (Triton) $407,876 18 payments
  3. A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (TRITON) $245,394 33 payments
  4. An Open-Label Extension Trial of the Phase III Lipid-Lowering Trials to Assess the Effect of Long Term Dosing of Inclisiran Given As Subcutaneous Injections in Subjects With High Cardiovascular Risk and Elevated LDL-C $242,353 4 payments
  5. A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Effects of Bempedoic Acid (Etc-1002) on the Occurrence of Major Cardiovascular Events in Patients With, Or at High Risk For, Cardiovascular Disease Who Are Statin Intolerant $234,963 354 payments
  6. Randomized, double-blind, placebo- and active-controlled, parallel group, fixed -dose study in pediatric patients, ages 7-17 years. The study will be approximately 10 weeks in duration: 1-week screening/washout period, 8-week double-blind treatment peri $232,556 12 payments
  7. Open-Label Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia or Bipolar I Disorder $212,382 13 payments
  8. A Phase 3 Randomized Double Blind Placebo and Activecontrolled Multicenter Parallelgroup Study of the Analgesic Efficacy and Safety of Tanezumab in Adult Subjects With Chronic Low Back Pain $209,727 2 payments
  9. Iti-007-601 $189,743 70 payments
  10. A 52-Week, Randomised, Double-Blind, Placebo-Controlled, Parallel-Grou $186,279 25 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record